Cargando…

Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis

Detalles Bibliográficos
Autores principales:	Balak, Deepak MW, Hengstman, Gerald JD, Hupperts, Raymond, Thio, H Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242240/ http://dx.doi.org/10.1186/1479-5876-9-S2-P14

Ejemplares similares

Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
por: Balak, Deepak MW, et al.
Publicado: (2013)

Treatment of lupus erythematosus with fumaric acid ester derivatives: two case-reports
por: Balak, Deepak MW, et al.
Publicado: (2011)

Effects of immunomodulating therapies on mortality in patients with severe cutaneous adverse reactions in comparison with supportive care only: a systematic review
por: Zimmermann, Stefanie, et al.
Publicado: (2014)

Poster 2002: Transfer factor may provide immunomodulation in cutaneous tuberculosis
por: Vidal, Laura, et al.
Publicado: (2014)

Atopy in cutaneous and arthropatic psoriasis
por: Hajdarbegovic, E, et al.
Publicado: (2010)

Multiple drug hypersensitivity associated with severe cutaneous adverse reaction
por: Lin Choo, Karen Jui, et al.
Publicado: (2014)

Adverse events associated with long-term ketamine use in pediatric septic shock
por: Mangia, CMF, et al.
Publicado: (2011)

Analysis of B cell subsets in severe cutaneous adverse reaction
por: Azukizawa, Hiroaki, et al.
Publicado: (2014)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Epidemiology and nature of adverse events in the ICU
por: Ouerghi, S, et al.
Publicado: (2009)

Honey as an immunomodulator during sepsis in animal model
por: Kassim, M, et al.
Publicado: (2009)

Patch testing in drug cutaneous adverse reactions: value of the extemporaneous preparations
por: Assier, Haudrey, et al.
Publicado: (2014)

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
por: Kolb-Mäurer, Annette, et al.
Publicado: (2015)

Adverse drug events in the critical care unit
por: Seynaeve, S, et al.
Publicado: (2010)

Risk factors of mortality in severe cutaneous adverse reactions patients with pulmonary involvement
por: Hu, H, et al.
Publicado: (2012)

Incidence of adverse events in a Brazilian coronary ICU
por: Paula, VF, et al.
Publicado: (2014)

An immunohistochemical study of the granulysin expression of 6 types of proven adverse cutaneous drug reaction
por: Weinborn, Marie, et al.
Publicado: (2014)

P29 - Intestinal helminth Enterobius vermicularis as an immunomodulator factor
por: Patsantara, Giannoula, et al.
Publicado: (2014)

PA03.16. Role of herbal immunomodulators in Paediatric practice
por: Manohar, I Nilesh, et al.
Publicado: (2013)

SNP algorithms for prediction of efficacy and adverse events of abatacept (ABT)
por: Middleton, James E, et al.
Publicado: (2012)

Adverse medication events in the intensive care unit: avoidable or inevitable?
por: Mitchell, J, et al.
Publicado: (2005)

Minimal number of adverse physiological events during physiotherapy intervention
por: Paratz, J, et al.
Publicado: (2006)

Optimising patient recall of adverse events over prolonged time periods
por: Hiller, Louise, et al.
Publicado: (2011)

Patient safety in ICUs: adverse events characterization and potential risk factors
por: Zambon, L, et al.
Publicado: (2011)

Consequences of adverse events with handling of the orotracheal cannula in intensive care unit
por: Silva, S, et al.
Publicado: (2005)

Total ischemic myocardium is a powerful predictor for adverse cardiac events
por: Buckert, Dominik, et al.
Publicado: (2015)

Adverse events in patients in a Brazilian intensive care according to the readmission
por: Plantier, GM, et al.
Publicado: (2015)

Evaluation of the adverse events on applying a functional protocol in patients in an ICU
por: Maturana, Maíra J, et al.
Publicado: (2015)

Natural immunomodulator preimplantation factor PIF affected cancer growth in malignant melanomas
por: Kotlan, Beatrix, et al.
Publicado: (2014)

PA02.14. A review on immunomodulator activity of Yashtimadhu (Glycyrriza Glabra).
por: Kumar, Krishan, et al.
Publicado: (2013)

P22. Immunomodulation induced by resveratrol or genistein on proliferation and apoptosis of tumour colon cells
por: Brasoveanu, L, et al.
Publicado: (2014)

PA02.10. A review on immunomodulator activity of some indiginious medical plants
por: Dutt, S Brahm
Publicado: (2013)

PReS-FINAL-2033: Increase of adverse mild and moderate adverse events among patients with juvenile idiopathic arthritis treated with biological therapies
por: Guillen Astete, CA, et al.
Publicado: (2013)

Drugs inducing T-cell mediated cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells
por: Gonçalo, Margarida, et al.
Publicado: (2014)

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2014)

Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis
por: Tarkiainen, M, et al.
Publicado: (2008)

Saddle embolism is associated with the major adverse events in patients with nonhigh-risk pulmonary embolism
por: Kim, H, et al.
Publicado: (2012)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Septic shock and the use of norepinephrine in a high dependency unit - mortality and adverse events
por: Hallengren, M, et al.
Publicado: (2015)

P351: Undesirable adverse events of the thoracic surgery department of the institute of cardiology of Abidjan
por: Adeoti, M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ka65aol7mndsel0v2evd37dp91